Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 1.00 |
| ▸ | CA1 | P00915 | 11/20 | 1.00 |
| ▸ | CA12 | O43570 | 10/20 | 1.00 |
| ▸ | CA9 | Q16790 | 10/20 | 1.00 |
| ▸ | NAMPT | P43490 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | CA7 | P43166 | 4/20 | 0.67 |
| ▸ | CA5A | P35218 | 3/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20389230 | 0.86 | NAMPT (1.00) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL14726350 | 0.85 | CA2 (0.74) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL11887680 | 0.84 | ALDH1A1 (1.00) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL20388977 | 0.84 | NAMPT (0.85) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL165262 | 0.84 | NAMPT (0.80) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL31241518 | 0.84 | NAMPT (0.80) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL671546 | 0.82 | CA2 (1.00) | CA2CA1CA12CA9CA7 | |
| SCHEMBL2831462 | 0.82 | NPC1 (0.77) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL14323871 | 0.82 | CA2 (0.67) | CA2CA1CA12CA9NAMPT | |
| SCHEMBL3461361 | 0.81 | CA2 (0.68) | CA2CA1CA12CA9NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | claimed |
| CN-103221388-A | Novel sulfonamide compounds for inhibition of metastatic tumor growth | METASIGNAL THERAPEUTICS INC | 2013-07-24 | — | — | CN | claimed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | claimed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | claimed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-9962398-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2018-05-08 | — | — | US | disclosed |
| US-9962398-B2 | Sulfonamide compounds for inhibition of metastatic tumor growth | WELICHEM BIOTECH INC. (CA) | 2018-05-08 | — | — | US | disclosed |
| EP-3217970-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | Del Mar Pharmaceuticals (CA) | 2017-09-20 | — | — | EP | disclosed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | disclosed |
| EP-2590938-B1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC (CA) | 2017-06-07 | — | — | EP | disclosed |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | WELICHEM BIOTECH INC. (CA) | 2017-01-12 | — | — | US | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2013-07-25 | — | — | US | disclosed |
| CN-103221388-A | Novel sulfonamide compounds for inhibition of metastatic tumor growth | METASIGNAL THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| EP-2590938-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | Metasignal Therapeutics Inc. (CA) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012021963-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | METASIGNAL THERAPEUTICS INC. (CA) | 2012-02-23 | — | — | WO | disclosed |
| CN-1330705-C | Flame retardant aromatic poly cabonic ester resin composition and finished products | TEIJIN CHEMICAL CO LTD (JP) | 2007-08-08 | — | — | CN | disclosed |
| CN-1408767-A | Flame retardant aromatic poly cabonic ester resin composition and finished products | TEIJIN CHEMICAL CO LTD (JP) | 2003-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190396-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA2 5/4885CA1 31/4885CA12 61/4885 |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | MGMT, DCLRE1A, DNMT1 | CA2 4654/4885CA1 2097/4885CA12 1160/4885 |
| US-20170007627-A1 | NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH | HIF1AN, CBX2, HIF1A | CA2 5/4885CA1 31/4885CA12 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.